B+
Bull case
25%
Probability
Target price
$6.00
+142.9% vs current
GRCE
Grace TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$2.75
+11.3% vs current
B-
Bear case
30%
Probability
Target price
$0.90
-63.6% vs current
AI sentiment snapshot
Latest data as of 2026-06-26
Recent news sentiment (30D)
-0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+67.3
Score
AI commentary
Primary-source evidence quality is high because the June 18 SEC-filed earnings release is usable, but the thesis remains cautious: the deterministic prior is negative, the company’s own update confirms the story is now about fixing a CRL rather than approaching approval, and T+3 follow-up evidence still lacks confirmed delayed analyst-revision support or a well-sourced market-reaction narrative. With no usable social packet and no trusted reaction data beyond the anchor price of $2.37 on June 25, 2026, this remains a low-conviction monitoring setup rather than a strong post-earnings recovery call.
RankAlpha Sentiment Codex - 2026-06-26
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-26catalystPost-CRL setup is narrower than a clinical failure, but still needs proof of executionHigh impact
The June 18 company earnings release filed on Form 8-K said the April 23 FDA Complete Response Letter for GTx-104 cited CMC, non-clinical, and contract-manufacturing cGMP items, with no clinical deficiencies identified. That keeps the near-term debate focused on remediation execution rather than efficacy, but the stock still needs evidence that management can convert that distinction into a credible resubmission path [#SEC-8K-2026-06-18].
2026-09-24eventType A meeting minutes are the key regulatory checkpoint for GTx-104High impact
Management said a Type A meeting with the FDA has been scheduled and that the company expects to provide a regulatory update after receipt of official meeting minutes. For a single-asset small-cap biotech, that readout is now the clearest trigger for whether NDA resubmission timing becomes more concrete or slips further [#SEC-8K-2026-06-18].
2027-03-31catalystCash and lower R&D burn support remediation work, but financing risk remains if the FDA loop extendsHigh impact
The June 18 filing said Grace ended March 31, 2026 with $17.0 million of cash and cash equivalents, while FY2026 R&D expense fell to $2.4 million from $9.5 million as the Phase 3 STRIVE-ON trial wound down. That gives the company resources to work through the CRL, but a prolonged manufacturing or non-clinical fix would still raise dilution risk because GRCE remains a low-cap, one-program story [#SEC-8K-2026-06-18].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-26 • Updated nightlySource: Internal modelMethodology